CA2795289A1 - Methods and compositions for enhanced delivery of compounds - Google Patents

Methods and compositions for enhanced delivery of compounds Download PDF

Info

Publication number
CA2795289A1
CA2795289A1 CA2795289A CA2795289A CA2795289A1 CA 2795289 A1 CA2795289 A1 CA 2795289A1 CA 2795289 A CA2795289 A CA 2795289A CA 2795289 A CA2795289 A CA 2795289A CA 2795289 A1 CA2795289 A1 CA 2795289A1
Authority
CA
Canada
Prior art keywords
composition
molecules
homing
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2795289A
Other languages
English (en)
French (fr)
Inventor
Erkki Ruoslahti
Lilach Agemy
Dinorah Friedmann-Morvinski
Venkata Ramana Kotamraju
Kazuki Sugahara
Inder Verma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Salk Institute for Biological Studies
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute, Salk Institute for Biological Studies filed Critical Sanford Burnham Prebys Medical Discovery Institute
Publication of CA2795289A1 publication Critical patent/CA2795289A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2795289A 2010-04-08 2011-04-08 Methods and compositions for enhanced delivery of compounds Abandoned CA2795289A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32220710P 2010-04-08 2010-04-08
US61/322,207 2010-04-08
US37685610P 2010-08-25 2010-08-25
US61/376,856 2010-08-25
PCT/US2011/031785 WO2011127405A1 (en) 2010-04-08 2011-04-08 Methods and compositions for enhanced delivery of compounds

Publications (1)

Publication Number Publication Date
CA2795289A1 true CA2795289A1 (en) 2011-10-13

Family

ID=44120964

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2795289A Abandoned CA2795289A1 (en) 2010-04-08 2011-04-08 Methods and compositions for enhanced delivery of compounds

Country Status (5)

Country Link
US (2) US20110262347A1 (cg-RX-API-DMAC10.html)
EP (1) EP2555802A1 (cg-RX-API-DMAC10.html)
JP (1) JP2013525285A (cg-RX-API-DMAC10.html)
CA (1) CA2795289A1 (cg-RX-API-DMAC10.html)
WO (1) WO2011127405A1 (cg-RX-API-DMAC10.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10363309B2 (en) * 2011-02-04 2019-07-30 Case Western Reserve University Targeted nanoparticle conjugates
WO2012135550A1 (en) * 2011-03-30 2012-10-04 Luna Innovations Incorporated Biomarker-targeting contrast agents and their use in magnetic resonance imaging for detection of atherosclerotic plaque
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
US20130195752A1 (en) 2012-02-01 2013-08-01 Regents Of The University Of Minnesota Functionalized nanoparticles and methods of use thereof
US20130217765A1 (en) * 2012-02-16 2013-08-22 Eric Brown Multifunctional nanoconjugates and uses thereof
EP2671597A1 (en) * 2012-06-07 2013-12-11 Cepep III AB Chimeric constructs between glioma-homing peptide and cell-penetrating peptides, gHoPe2
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CN106794217A (zh) * 2014-08-06 2017-05-31 血管生物科学 包含对患病组织具有选择性的药效团的组合物及其制备方法
EP3183007B1 (en) * 2014-08-19 2020-06-17 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
BR112017007012A2 (pt) 2014-10-06 2018-03-06 Exicure Inc compostos anti-tnf
EP3017809A1 (en) * 2014-11-07 2016-05-11 Ferring B.V. Drug-device unit containing quinagolide
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2016172515A1 (en) 2015-04-23 2016-10-27 Sanford Burnham Prebys Medical Discovery Institute Targeted delivery system and methods of use therefor
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN105055315B (zh) * 2015-08-03 2017-10-31 四川大学 一种交联线粒体靶向阿霉素脂质体及其制备方法
CN106220735A (zh) * 2015-09-11 2016-12-14 中山大学 一种组织蛋白酶b激活式靶向抗肿瘤多肽的制备与应用
CN105395483B (zh) * 2015-12-21 2018-09-28 江南大学 一种可还原降解超支化聚合物纳米胶束及其制备方法
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018085050A1 (en) 2016-11-03 2018-05-11 Sanford Burnham Prebys Medical Discovery Institute Compositions and methods for imaging tissues and tumors
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
AU2017384425B2 (en) 2016-12-21 2023-08-31 Nanobiotix Nanoparticles for use for treating a neuronal disorder
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CN111712468A (zh) 2017-12-22 2020-09-25 北卡罗莱纳州立大学 聚合物荧光团、包含其的组合物及制备和使用其的方法
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
WO2020190556A1 (en) * 2019-03-18 2020-09-24 Novomer, Inc. Membrane separation system, and uses thereof
WO2021242917A1 (en) * 2020-05-27 2021-12-02 Georgetown University Targeting the cholecystokinin-b receptor for imaging and early detection of pancreatic cancer and pre-cancerous lesions
US20250332265A1 (en) 2021-11-09 2025-10-30 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
CN114106108B (zh) * 2021-11-25 2023-07-14 中国石油大学(华东) 一种多肽-金纳米颗粒复合物、其制备方法及应用
CN114732796B (zh) * 2022-02-18 2023-01-17 北京大学第三医院(北京大学第三临床医学院) 一种双靶向载药微泡及其制备方法和应用
WO2025186514A1 (en) * 2024-03-07 2025-09-12 University Of Helsinki Cancer cell targeting peptide
WO2026150165A1 (en) * 2025-01-09 2026-07-16 Tampere University Foundation Sr Tissue-penetrating homing peptides, peptide conjugates and compositions comprising the same

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1016978B (de) 1955-05-16 1957-10-03 Iashellia Res Ltd Mittel zur Bekaempfung des Pflanzenwachstums
FR1601438A (cg-RX-API-DMAC10.html) 1968-10-17 1970-08-24
CH588887A5 (cg-RX-API-DMAC10.html) 1974-07-19 1977-06-15 Battelle Memorial Institute
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4418052A (en) 1980-08-12 1983-11-29 Wong Dennis W Diagnostic compositions and method for radiologic imaging of fibrinogen deposition in the body
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
GB8416234D0 (en) 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
US4761288A (en) 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
US5628936A (en) 1987-03-13 1997-05-13 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
US5474848A (en) 1987-03-13 1995-12-12 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4853228A (en) 1987-07-28 1989-08-01 Micro-Pak, Inc. Method of manufacturing unilamellar lipid vesicles
US5011686A (en) 1987-09-21 1991-04-30 Creative Biomolecules, Inc. Thrombus specific conjugates
US5013497A (en) 1988-03-03 1991-05-07 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5024829A (en) 1988-11-21 1991-06-18 Centocor, Inc. Method of imaging coronary thrombi
JP2517760B2 (ja) 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5792742A (en) 1991-06-14 1998-08-11 New York University Fibrin-binding peptide fragments of fibronectin
FR2735658B1 (fr) 1995-06-21 1997-09-12 Capsulis Encapsulation de composes a usage alimentaire par des tensioactifs
KR940003548U (ko) 1992-08-14 1994-02-21 김형술 세탁물 건조기
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
CA2163860A1 (en) 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
US5536814A (en) 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5789542A (en) 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
JP4036472B2 (ja) 1995-04-14 2008-01-23 一則 片岡 片末端に糖、他末端に異なる官能基を有するポリエチレンオキシド及びその製造方法
KR19990007861A (ko) 1995-04-19 1999-01-25 가타오카가즈노리 헤테로테레케릭 블록 공중합체 및 이의 제조방법
WO1997006202A1 (en) 1995-08-10 1997-02-20 Kazunori Kataoka Block polymer having functional groups at both ends
US5897945A (en) 1996-02-26 1999-04-27 President And Fellows Of Harvard College Metal oxide nanorods
US6506564B1 (en) 1996-07-29 2003-01-14 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
KR20000076363A (ko) 1997-03-18 2000-12-26 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 Dna 라이브러리를 제조하기 위한 시험관내 방법
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
NZ508669A (en) 1998-06-11 2003-06-30 Dimensional Pharm Inc Pyrazinone protease inhibitors
EP1150701A4 (en) * 1999-01-22 2003-03-26 Burnham Inst TARGETING PRO-APOPTOTIC CONJUGATES AND METHODS FOR USE THEREOF
US6530944B2 (en) 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
ATE346074T1 (de) 2000-11-30 2006-12-15 Penn State Res Found Dna methyl transferase inhibitoren
US7192921B2 (en) 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
ATE419861T1 (de) * 2001-11-08 2009-01-15 Burnham Inst Peptide mit homing für lymphgefässtumor und ihre verwendung
WO2003087124A2 (en) * 2002-04-05 2003-10-23 The Burnham Institute Hmgn2 peptides and related melecules that selectively home to tumor blood vessels and tumor cells
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
US7723474B2 (en) * 2003-10-21 2010-05-25 The Regents Of The University Of California Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
CN103169729A (zh) * 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
WO2007090194A2 (en) 2006-02-01 2007-08-09 The Burnham Institute For Medical Research Lymphatic zip codes in tumors and pre-malignant lesions
WO2008100328A2 (en) 2006-07-13 2008-08-21 Burnham Institute For Medical Research METHODS AND COMPOSITIONS FOR TARGETING gC1qR/p32
US8188220B2 (en) 2006-12-06 2012-05-29 Sanford-Burnham Medical Research Institute Methods and compositions related to targeting wounds, regenerating tissue, and tumors
JP2010514839A (ja) 2007-01-03 2010-05-06 バーナム インスティテュート フォー メディカル リサーチ クロット結合化合物に関連する方法および組成物
US8367621B2 (en) 2008-01-18 2013-02-05 Sanford-Burnham Medical Research Institute Methods and compositions related to internalizing RGD peptides
ES2951646T3 (es) * 2008-02-21 2023-10-24 Burnham Institute For Medical Res Métodos y composiciones relacionados con péptidos y proteínas con elementos C-terminales
US20100254914A1 (en) * 2009-02-25 2010-10-07 The Regents Of The University Of California Nanoworms for in vivo tumor targeting
CN102869384B (zh) 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物

Also Published As

Publication number Publication date
WO2011127405A1 (en) 2011-10-13
JP2013525285A (ja) 2013-06-20
EP2555802A1 (en) 2013-02-13
US20110262347A1 (en) 2011-10-27
WO2011127405A9 (en) 2011-11-17
US20170246236A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
US20170246236A1 (en) Methods and compositions for enhanced delivery of compounds
US12195558B2 (en) Targeted delivery system and methods of use therefor
US20210260202A1 (en) Methods and Compositions Related to Annexin 1-Binding Compounds
US9101671B2 (en) Methods and compositions related to clot binding compounds
US20120034164A1 (en) Truncated car peptides and methods and compositions using truncated car peptides
US20090036349A1 (en) Methods and Compositions Related to Targeting Wounds, Regenerating Tissue, and Tumors
US10179801B2 (en) Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
WO2018204392A1 (en) Tumor associated monocyte/macrophage binding peptide and methods of use thereof
US8912136B2 (en) Methods and compositions related to clot-binding compounds
US20220119450A1 (en) Bi-specific extracellular matrix binding peptides and methods of use thereof
WO2012118778A1 (en) Truncated car peptides and methods and compositions using truncated car peptides
US20130058993A1 (en) Methods and compositions for enhancing wound healing using car peptides
HK1176299A (en) Methods and compositions related to annexin 1-binding compounds
HK1176299B (en) Methods and compositions related to annexin 1-binding compounds

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160408